Toxicities Following CAR-T Therapy for Hematological Malignancies
Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in relapsed/refractory patients with hematological malignancies, including B-acute lymphoblastic leukemia (B-ALL), large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL) and multiple myeloma (MM). The following CAR-T products are licensed in Europe and United States: tisagenlecleucel (tisa-cel) (Kymriah ®) for pediatric B-ALL [1] and LBCL [2]; axicabtagene ciloleucel (axi-cel) (Yescarta®) and lisocabtagene maraleucel (Breyanzi®) for LBCL [3,4]; brexucabtagene autoleucel (Tecartus®) for MCL [5]; idecabtagene vicleucel (Abecma®) for MM [6]. (Source...
Source: Cancer Treatment Reviews - October 22, 2022 Category: Cancer & Oncology Authors: Rafael Hernani, Ana Benzaqu én, Carlos Solano Source Type: research
Response to ‘Considerations Regarding a Network Meta-analysis of Targeted Therapies for BRAF Mutant Unresectable or Metastatic Melanoma’
To the Editor (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 21, 2022 Category: Cancer & Oncology Authors: Pippa Corrie, Nicolas Meyer, Rossana Berardi, Massimo Guidoboni, Max Schlueter, Spyros Kolovos, B érengère Macabeo, Jean-Baptiste Trouiller, Philippe Laramée Tags: Hot Topic Source Type: research
The conundrum of breast cancer and microbiome - A comprehensive review of the current evidence
The human body hosts a wide range of damaging and beneficial bacteria in balance, described as symbiosis or eubiosis. Sometimes this equilibrium is disrupted, leading to dysbiosis, which can have detrimental consequences on the health of the individual, leading to various pathological conditions, including neoplasia [1 –2]. Polymorphic microbiomes in the gut have been recently recognized as emerging mechanisms that enable cancer hallmark capabilities and there is an increasing interest on the significance of intratumoral microbiomes in cancer pathogenesis and natural history [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 12, 2022 Category: Cancer & Oncology Authors: Andri Papakonstantinou, Paolo Nuciforo, Maria Borrell, Esther Zamora, Isabel Pimentel, Cristina Saura, Mafalda Oliveira Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 11, 2022 Category: Cancer & Oncology Source Type: research
Considerations Regarding a Network Meta-analysis of Targeted Therapies for BRAF-Mutant Unresectable or Metastatic Melanoma
To the Editor (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 8, 2022 Category: Cancer & Oncology Authors: Alessandro Rizzo Tags: Hot Topic Source Type: research
HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage
Human papillomavirus (HPV) is part of the Papillomaviridae family of double-stranded DNA viruses that infect epithelial cells of both the skin and the genital and oral mucosa [1]. There are more than 200 HPV genotypes; approximately 13 are considered high-risk (HR) or oncogenic to humans, with HPV16 and 18 causing more than 70% of all HPV-related malignancies in men and women [2 –3]. Low risk types (HPV 6 and 11 being the most frequent) induce genital warts and recurrent respiratory papillomatosis [2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 5, 2022 Category: Cancer & Oncology Authors: Gaia Giannone, Anna R. Giuliano, Marco Bandini, Laura Marandino, Daniele Raggi, Wayne Earle, Benjamin Ayres, Curtis A. Pettaway, Iain A. McNeish, Philippe E. Spiess, Andrea Necchi Source Type: research
Multiple Bayesian Network Meta-Analyses to Establish Therapeutic Algorithms for Metastatic Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast tumors and is defined by the absence of endocrine receptors (ER) and HER2 gene overexpression/amplification.[1] Metastatic TNBC (mTNBC) remains an incurable disease with unfavorable prognosis[2]. However, the scenario is quickly changing. 10.6 - 41.9% TNBC harbor a germline mutation in the homologous recombination repair (HRR) genes BRCA1/2.[3] In these cases, following positive results from respective pivotal trials, it is now possible to administer the PARP-inhibitors (PARPi) olaparib or talazoparib in first or further lines. (Source: Canc...
Source: Cancer Treatment Reviews - September 27, 2022 Category: Cancer & Oncology Authors: Francesco Schettini, Sergio Venturini, Mario Giuliano, Matteo Lambertini, David J. Pinato, Concetta Elisa Onesti, Pietro De Placido, Nadia Harbeck, Diana L üftner, Hannelore Denys, Peter Van Dam, Grazia Arpino, Khalil Zaman, Giorgio Mustacchi, Joseph Gli Source Type: research
Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”
The search of predictive biomarkers for immune checkpoint inhibitor (ICIs) therapy remains a topic of major interest in oncology research. Previous studies have suggested that the development of immune-related adverse events (irAEs) can be associated with efficacy of ICIs in different cancer types[1,2,3]. However, statistical caveats such as the immortal-time bias or the publication bias may have overestimated this association[4]. Recently, Kfoury et alhave analysed 577 patients treated with anti-PD-(L)1 antibodies at Gustave Roussy Institute to evaluate the association of irAEs and efficacy outcomes after correctly accoun...
Source: Cancer Treatment Reviews - September 23, 2022 Category: Cancer & Oncology Authors: Guillermo Villacampa, Alberto Hernando-Calvo, Roger Berch é, Omar Saavedra, David Marmolejo, Oriol Mirallas, Irene Braña, Eva Muñoz-Couselo, Elena Garralda, Rodrigo Dienstmann Tags: Hot Topic Source Type: research
Lost in Translation: Revisiting the use of Tyrosine Kinase inhibitors in Colorectal Cancer
Colorectal cancer (CRC) is the 4th most lethal cancer in the world approximately causing 900,000 deaths every year. Recent advances in treatment options including surgery, radiotherapy, chemotherapy, and targeted therapy —along with early diagnosis—have improved the overall survival (OS) rate of patients with CRC [1]. In the cases of metastatic disease, fluoropyrimidine with either oxaliplatin and/or irinotecan (FOLFOXIRI/FOLFOX/FOLFIRI), often combined with bevacizumab or epidermal growth receptor (EGFR; cetuxi mab or panitumumab) are used as first-line chemotherapy regimens [2,3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 20, 2022 Category: Cancer & Oncology Authors: Kirti K. Iyer, Nielka P. van Erp, Daniele V.F. Tauriello, Henk M.W. Verheul, Dennis Poel Tags: Laboratory-Clinic Interface Source Type: research
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis
With an estimated number of deaths of almost 1.8 million in 2020, lung cancer is the most common cause of cancer-related death worldwide [1]. Of these, up to 85% are non-small cell lung cancers (NSCLCs), a disease entity which encompasses distinct mutational and histological subtypes, [2]. Given the extremely poor survival rates of advanced and metastatic NSCLC, increasing efforts have been made to design screening programs for high-risk populations (e.g. heavy smokers). Therefore, other than a mortality benefit [3], it is expected that the prevalence of early-stage NSCLC (ES-NSCLC) will increase in the upcoming years. (So...
Source: Cancer Treatment Reviews - September 20, 2022 Category: Cancer & Oncology Authors: Stefania Volpe, Gaia Piperno, Francesca Colombo, Annalisa Biffi, Stefania Comi, Federico Mastroleo, Anna Maria Camarda, Alessia Casbarra, Federica Cattani, Giulia Corrao, Filippo de Marinis, Lorenzo Spaggiari, Matthias Guckenberger, Roberto Orecchia, Dani Source Type: research
Oligometastatic breast cancer: dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?
In the last years we have witnessed unprecedented improvements of breast cancer (BC)-related survival, mostly driven by the progressive enhancement of the therapeutic armamentarium with increasingly effective treatment strategies[1]. Approximately 20-30% of patients with early-stage disease will eventually experience disease relapse and 5% are diagnosed with de-novo stage IV disease[2,3]. Once metastatic, BC is traditionally considered an incurable condition, where treatment choices, although potentially aimed at prolonging survival, are typically driven by palliative motives. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 5, 2022 Category: Cancer & Oncology Authors: Federica Miglietta, Luca Visani, Sabrina Marini, Gaia Griguolo, Grazia Maria Vernaci, Michele Bottosso, Maria Vittoria Dieci, Icro Meattini, Valentina Guarneri Tags: Hot Topic Source Type: research
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
A number of approved treatment options currently exist for BRAF-mutant patients with unresectable or metastatic melanoma (MM), and effective diagnosis tools are available for assessing BRAF mutational status [1 –3]. Clinician judgment drives individualized treatment decisions based on characteristics of the patient and of the disease [4]. Since multiple options exist, it is essential that treatment decisions are informed by relevant and contemporary clinical research, including efficacy and safety data. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 5, 2022 Category: Cancer & Oncology Authors: Corrie Pippa, Meyer Nicolas, Berardi Rossana, Guidoboni Massimo, Schlueter Maximilian, Kolovos Spyros, Macabeo B érengère, Trouiller Jean-Baptiste, Laramée Philippe Source Type: research
Indoleamine 2,3-dioxygenase (IDO) Inhibitors and Cancer Immunotherapy
The development and approval of immune checkpoint (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4], and lymphocyte-activation gene 3 [LAG-3]) inhibitors resulted in dramatic changes in the landscape of cancer therapy. Still, most patients treated with an immune checkpoint inhibitor, especially with a monotherapy approach, will demonstrate either primary or acquired resistance to these treatments, which has led to clinical research focusing on therapeutic options utilizing combination strategies with immune checkpoint inhibitors and other agents...
Source: Cancer Treatment Reviews - August 30, 2022 Category: Cancer & Oncology Authors: Yu Fujiwara, Shumei Kato, Mary K Nesline, Jeffrey M Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock Source Type: research
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
Immune checkpoint inhibitors (ICIs) have profoundly changed the therapeutic landscape and outcome of many solid tumours [1,2]. In metastatic colorectal cancer (mCRC), however, ICIs are effective only for the small group (about 5%) of patients with mismatch repair deficient (dMMR)/high microsatellite instable (MSI-H) tumours [3,4]. Pembrolizumab, and nivolumab (+/- ipilimumab) were first approved by international regulatory authorities, based on the impressive results of nonrandomised studies conducted in this patient population [5 –7]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 27, 2022 Category: Cancer & Oncology Authors: Tugba Akin Telli, Giacomo Bregni, Michele Van Hooren, Rita Saude Conde, Alain Hendlisz, Francesco Sclafani Source Type: research
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis
Low grade serous ovarian and peritoneal cancer (LGSC) is a rare subtype, representing 2% of all epithelial ovarian carcinomas (EOCs) [1]. Because of its rarity, very little is still known about its pathogenesis, molecular biology and, consequently, about the best applicable therapeutic strategies. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 23, 2022 Category: Cancer & Oncology Authors: Lucia Musacchio, Anna Amela Valsecchi, Vanda Salutari, Giorgio Valabrega, Floriana Camarda, Valentina Tuninetti, Gaia Giannone, Michele Bartoletti, Claudia Marchetti, Sandro Pignata, Anna Fagotti, Giovanni Scambia, Massimo Di Maio, Domenica Lorusso Tags: Anti-tumour Treatment Source Type: research
